Correction to: Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study (Diabetologia, (2012), 55, 7, (1963-1970), 10.1007/s00125-012-2545-x);Sex differences in the association between plasma copeptin and incident type 2 diabetes: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study

Diabetologia

Volumn 55, Issue 7, 2012, Pages 1963-1970

  Abbasi, A ^a   Corpeleijn, E ^a   Meijer, E ^a   Postmus, D ^a   Gansevoort, R T ^a   Gans, R O B ^a   Struck, J ^b   Hillege, H L ^a   Stolk, R P ^a   Navis, G ^a   Bakker, S J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

Copeptin; Prediction; Sex; Type 2 diabetes; Vasopressin

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; COPEPTIN; GLUCOSE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; URINARY EXCRETION;

EID: 84866362758     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-019-4917-y     Document Type: Erratum

References (39)

1. Aoyagi T, Birumachi J, Hiroyama M et al (2007) Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 148:2075-2084
2. Zerbe RL, Vinicor F, Robertson GL (1979) Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes 28:503-508
3. Struck J, Morgenthaler NG, Bergmann A (2005) Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 26:2500-2504
4. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT (2010) Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 77:29-36
5. Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112-119
6. Enhorning S, Wang TJ, Nilsson PM et al (2010) Plasma copeptin and the risk of diabetes mellitus. Circulation 121:2102-2108
7. Kirk CJ, Rodrigues LM, Hems DA (1979) The influence of vasopressin and related peptides on glycogen phosphorylase activity and phosphatidylinositol metabolism in hepatocytes. Biochem J 178:493-496
8. Oshikawa S, Tanoue A, Koshimizu TA, Kitagawa Y, Tsujimoto G (2004) Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. Mol Pharmacol 65:623-629
9. Tanoue A, Ito S, Honda K et al (2004) The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 113:302-309
10. Fujiwara Y, Hiroyama M, Sanbe A et al (2007) Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J Physiol 584:235-244
11. Stachenfeld NS, Splenser AE, Calzone WL, Taylor MP, Keefe DL (2001) Sex differences in osmotic regulation of AVP and renal sodium handling. J Appl Physiol 91:1893-1901
12. Simmler LD, Hysek CM, Liechti ME (2011) Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab 96:2844-2850
13. Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT (2005) Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 28:2525-2530
14. Halimi JM, Bonnet F, Lange C, Balkau B, Tichet J, Marre M (2008) Urinary albumin excretion is a risk factor for diabetes mellitus in men, independently of initial metabolic profile and development of insulin resistance. The DESIR Study. J Hypertens 26:2198-2206
15. Thorand B, Lowel H, Schneider A et al (2003) C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 163:93-99
16. Thorand B, Baumert J, Kolb H et al (2007) Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 30:854-860
17. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334
18. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT (2008) Albuminuria assessed from firstmorning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 168:897-905
19. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT (2002) Pharmacy data in epidemiological studies: an easy to obtain and reliable tool. Pharmacoepidemiol Drug Saf 11:379-384
20. Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B (2009) Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 94:123-129
21. Abbasi A, Corpeleijn E, Postmus D et al (2011) Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia 54:2463-2465
22. Balkau B, Lange C, Fezeu L et al (2008) Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 31:2056-2061
23. Pencina MJ, DAgostino RB Sr, Steyerberg EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30:11-21
24. Cook NR, Ridker PM (2009) Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 150:795-802
25. American Diabetes Association (2007) Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1:S4-S41
26. Buijsse B, Simmons RK, Griffin SJ, Schulze MB (2011) Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev 33:46-62
27. Collins GS, Mallett S, Omar O, Yu LM (2011) Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med 9:103
28. McGeechan K, Macaskill P, Irwig L, Liew G, Wong TY (2008) Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide. Arch Intern Med 168:2304-2310
29. Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG, Melander O (2011) Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 96:E1065-E1072
30. Saleem U, Khaleghi M, Morgenthaler NG et al (2009) Plasma carboxyterminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 94:2558-2564
31. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL (2009) Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 116:257-263
32. Salomaa V, Havulinna A, Saarela O et al (2010) Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One 5:e10100
33. Ding EL, Song Y, Malik VS, Liu S (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295:1288-1299
34. Herder C, Karakas M, Koenig W (2011) Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther 90:52-66
35. Nakamura K, Aoyagi T, Hiroyama M et al (2009) Both V (1A) and V (1B) vasopressin receptors deficiency result in impaired glucose tolerance. Eur J Pharmacol 613:182-188
36. Kajantie E, Phillips DI (2006) The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology 31:151-178
37. Rhodes ME, Rubin RT (1999) Functional sex differences (žsexual diergism') of central nervous system cholinergic systems, vasopressin, and hypothalamic-pituitary-adrenal axis activity in mammals: a selective review. Brain Res Brain Res Rev 30:135-152
38. Lancet (2011) Taking sex into account in medicine. Lancet 378:1826
39. Oertelt-Prigione S, Parol R, Krohn S, Preissner R, Regitz-Zagrosek V (2010) Analysis of sex and gender-specific research reveals a common increase in publications and marked differences between disciplines. BMC Med 8:70